Apremilast effective in Behcet´s Syndrome
The oral phosphodiesterase (PDE)4 inhibitor apremilast displayed a significant effect on ulcers and ulcer pain associated with Behcet´s syndrome in the RELIEF trial . Behcet´s syndrome is a rare, chronic, multi-system inflammatory disorder characterised by oral and genital ulcers, skin lesions, uveitis, arthritis, with vascular, central nervous system, and gastrointestinal involvement.
A key symptom occurring in nearly all patients is painful recurrent oral ulcers that can be disabling and have a substantial effect on QoL: there are currently no effective treatment options for them. The oral PDE4 inhibitor apremilast modulates inflammatory mediators and has demonstrated efficacy in a Phase 2 Behcet´s syndrome study. These preliminary data were the reason for a Phase 3 trial with apremilast.
In the RELIEF study, a total of 207 patients were randomised to apremilast (30 mg twice daily) or placebo. A...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Choice of taxane and addition of pembrolizumab for metastatic squamous non-small-cell lung cancer Next Article
IL-4/IL-13 inhibition »
Table of Contents: AAD 2018
Psoriasis: an update
What's hot in atopic dermatitis
Pearls of the posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.